These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 31477544)

  • 41. Cost-effectiveness and budget impact of the community-based management of hypertension in Nepal study (COBIN): a retrospective analysis.
    Krishnan A; Finkelstein EA; Kallestrup P; Karki A; Olsen MH; Neupane D
    Lancet Glob Health; 2019 Oct; 7(10):e1367-e1374. PubMed ID: 31537367
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
    Ostovaneh MR; Poustchi H; Hemming K; Marjani H; Pourshams A; Nateghi A; Majed M; Navabakhsh B; Khoshnia M; Jaafari E; Mohammadifard N; Malekzadeh F; Merat S; Sadeghi M; Naemi M; Etemadi A; Thomas GN; Sarrafzadegan N; Cheng KK; Marshall T; Malekzadeh R
    Eur J Prev Cardiol; 2015 Dec; 22(12):1609-17. PubMed ID: 25230980
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study.
    Aguiar C; Araujo F; Rubio-Mercade G; Carcedo D; Paz S; Castellano JM; Fuster V
    J Health Econ Outcomes Res; 2022; 9(2):134-146. PubMed ID: 36475278
    [No Abstract]   [Full Text] [Related]  

  • 44. Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis.
    Marx FM; Cohen T; Menzies NA; Salomon JA; Theron G; Yaesoubi R
    Lancet Glob Health; 2020 Sep; 8(9):e1223-e1233. PubMed ID: 32827484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-Effectiveness of Improved Hypertension Management in India through Increased Treatment Coverage and Adherence: A Mathematical Modeling Study.
    Das H; Moran AE; Pathni AK; Sharma B; Kunwar A; Deo S
    Glob Heart; 2021 May; 16(1):37. PubMed ID: 34040950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.
    Bautista LE; Vera-Cala LM; Ferrante D; Herrera VM; Miranda JJ; Pichardo R; Sánchez Abanto JR; Ferreccio C; Silva E; Oróstegui Arenas M; Chirinos JA; Medina-Lezama J; Pérez CM; Schapochnik N; Casas JP
    Health Aff (Millwood); 2013 Jan; 32(1):155-64. PubMed ID: 23297283
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of antivenoms for snakebite envenoming in Nigeria.
    Habib AG; Lamorde M; Dalhat MM; Habib ZG; Kuznik A
    PLoS Negl Trop Dis; 2015 Jan; 9(1):e3381. PubMed ID: 25569252
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population.
    van Gils PF; Over EA; Hamberg-van Reenen HH; de Wit GA; van den Berg M; Schuit AJ; Engelfriet PM
    BMJ Open; 2011; 1(2):e000363. PubMed ID: 22189351
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
    Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
    Lancet Glob Health; 2013 Dec; 2(1):23-34. PubMed ID: 25083415
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic evaluation of participatory learning and action with women's groups facilitated by Accredited Social Health Activists to improve birth outcomes in rural eastern India.
    Sinha RK; Haghparast-Bidgoli H; Tripathy PK; Nair N; Gope R; Rath S; Prost A
    Cost Eff Resour Alloc; 2017; 15():2. PubMed ID: 28344517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction.
    Ito K; Shrank WH; Avorn J; Patrick AR; Brennan TA; Antman EM; Choudhry NK
    Health Serv Res; 2012 Dec; 47(6):2097-117. PubMed ID: 22998129
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fixed-combination, low-dose, triple-pill antihypertensive medication versus usual care in patients with mild-to-moderate hypertension in Sri Lanka: a within-trial and modelled economic evaluation of the TRIUMPH trial.
    Lung T; Jan S; de Silva HA; Guggilla R; Maulik PK; Naik N; Patel A; de Silva AP; Rajapakse S; Ranasinghe G; Prabhakaran D; Rodgers A; Salam A; Selak V; Stepien S; Thom S; Webster R; Lea-Laba T;
    Lancet Glob Health; 2019 Oct; 7(10):e1359-e1366. PubMed ID: 31477545
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative value-based pricing of an Ebola vaccine in resource-constrained countries based on cost-effectiveness analysis.
    Obeng-Kusi M; Erstad B; Roe DJ; Abraham I
    J Med Econ; 2022; 25(1):894-902. PubMed ID: 35748085
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of polypill for primary and secondary prevention of cardiovascular disease: a pragmatic cluster-randomised controlled trial (PolyPars).
    Malekzadeh F; Gandomkar A; Poustchi H; Etemadi A; Roshandel G; Attar A; Abtahi F; Sadeghi Boogar S; Mohammadkarimi V; Fattahi MR; Mohagheghi A; Malekzadeh R; Sepanlou SG
    Heart; 2024 Jun; 110(14):940-946. PubMed ID: 38485210
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
    Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
    Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of HIV prevention for high-risk groups at scale: an economic evaluation of the Avahan programme in south India.
    Vassall A; Pickles M; Chandrashekar S; Boily MC; Shetty G; Guinness L; Lowndes CM; Bradley J; Moses S; Alary M; ; Vickerman P
    Lancet Glob Health; 2014 Sep; 2(9):e531-e540. PubMed ID: 25304420
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
    Zhang L; Lin Z; Yin H; Liu J; Xuan J
    Clin Ther; 2018 Dec; 40(12):2125-2137. PubMed ID: 30470579
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.